Molecular characterization of mucolipidosis: A case-series from Iran.

GeneOct 21, 2026 (epub)

Mohadeseh Fathi, Sheyda Khalilian, Parvaneh Karimzadeh et al.

✦ AI-curated · Sources linked

Case in brief

Six unrelated Iranian patients with mucolipidosis underwent molecular characterization. Pathogenic homozygous variants were identified in GNPTAB, GNPTG, and MCOLN1, with all variants classified as pathogenic under ACMG guidelines and supported by ClinVar and gnomAD data. Two patients shared the GNPTAB variant c.3503_3504del (p.L1168Qfs*5). The report describes clinical and molecular features across mucolipidosis subtypes; the abstract does not provide individual presentations, diagnostic work-ups, or clinical outcomes.

What made this case unusual

Two unrelated cases carried the same homozygous GNPTAB frameshift variant, c.3503_3504del (p.L1168Qfs*5), among cases with variants across three mucolipidosis-associated genes.

Diagnostic / clinical pearl

Molecular testing can identify pathogenic variants across GNPTAB, GNPTG, and MCOLN1 and help characterize mucolipidosis subtypes; homozygous findings may be relevant when assessing consanguineous families.

Source

Published in Gene. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Medical Genetics

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.